We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-3.56%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.78B
AUM Growth
+$176M
Cap. Flow
-$78M
Cap. Flow %
-2.8%
Top 10 Hldgs %
39.13%
Holding
109
New
17
Increased
24
Reduced
19
Closed
12

Top Buys

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$94.3M
2
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$60.3M
3
AERI
Aerie Pharmaceuticals
AERI
+$54.9M
4
XENT
Intersect ENT, Inc
XENT
+$29.7M
5
CHRS icon
Coherus Oncology
CHRS
+$29.1M

Top Sells

Rank Stock Value
1
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$90.8M
2
CNC icon
Centene
CNC
+$19.7M
3
AXGN icon
Axogen
AXGN
+$18.7M
4
GKOS icon
Glaukos
GKOS
+$17.9M
5
ASND icon
Ascendis Pharma A/S
ASND
+$17M

Sector Composition

Rank Sector Weight
1 Healthcare 67.69%
2 Financials 0.96%
3 Consumer Discretionary 0.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$155M 5.59%
6,462,634
– –
VTRS icon
2
Viatris
VTRS
$20.1B
$142M 5.11%
7,464,327
+4,264,538
+133% +$94.3M
ORTX
3
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$125M 4.48%
892,360
+90,000
+11% +$15.8M
QTTB icon
4
Q32 Bio
QTTB
$255M
$113M 4.05%
320,020
+29,629
+10% +$11.6M
AERI
5
DELISTED
Aerie Pharmaceuticals
AERI
$89.6M 3.22%
3,032,987
+1,424,202
+89% +$54.9M
XENT
6
DELISTED
Intersect ENT, Inc
XENT
$70.8M 2.54%
3,109,004
+1,103,040
+55% +$29.7M
IMMU
7
DELISTED
Immunomedics Inc
IMMU
$69.1M 2.48%
4,985,383
+1,190,600
+31% +$17.9M
XLRN
8
DELISTED
Acceleron Pharma
XLRN
$53.6M 1.93%
1,305,174
+50,000
+4% +$2.07M
BKD icon
9
Brookdale Senior Living
BKD
$3.58B
$52M 1.87%
7,207,239
+2,045,884
+40% +$13.5M
RARX
10
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$51.5M 1.85%
1,713,000
+211,000
+14% +$4.83M
MYOK
11
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$50M 1.8%
997,000
– –
SRPT icon
12
Sarepta Therapeutics
SRPT
$1.82B
$47M 1.69%
309,025
-76,975
-20% -$9.36M
DPLO
13
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
$42.9M 1.54%
7,036,670
-12,627
-0.2% -$67.1K
ARGX icon
14
argenx
ARGX
$53.8B
$39.8M 1.43%
281,000
-112,750
-29% -$14.3M
VCEL icon
15
Vericel Corp
VCEL
$2.38B
$39.1M 1.4%
2,069,601
+380,601
+23% +$6.49M
MNK
16
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$38.4M 1.38%
+4,178,219
New +$60.3M
CHRS icon
17
Coherus Oncology
CHRS
$216M
$37.1M 1.33%
+1,678,022
New +$29.1M
BPMC
18
DELISTED
Blueprint Medicines
BPMC
$36.9M 1.33%
391,254
-115,611
-23% -$9.54M
FATE icon
19
Fate Therapeutics
FATE
$324M
$34.6M 1.24%
1,702,897
– –
ALEC icon
20
Alector
ALEC
$167M
$33.2M 1.19%
1,746,923
-210,000
-11% -$4.26M
SEM
21
DELISTED
Select Medical
SEM
$32.4M 1.16%
3,792,786
– –
ANAB icon
22
AnaptysBio
ANAB
$1.72B
$30.5M 1.1%
540,529
-202,910
-27% -$14.6M
EDIT icon
23
Editas Medicine
EDIT
$457M
$28.7M 1.03%
1,158,841
– –
SIEN
24
DELISTED
Sientra, Inc.
SIEN
$28.7M 1.03%
465,231
+192,168
+70% +$13.8M
NTRA icon
25
Natera
NTRA
$38.9B
$27.7M 0.99%
1,002,834
-320,000
-24% -$7.06M
1
2 3 4

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q2 2019 Portfolio in Review

As of Q2 2019, Deerfield Management held 109 positions worth $2.78B, up 6.8% from $2.61B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Deerfield Management's Q2 2019 filing shows 17 new, 24 increased, 19 reduced and 12 closed positions. Its largest new stake was MALLINCKRODT PUBLIC LIMITED COMPANY: 4,178,219 shares worth $38.4M. The largest sale was Portola Pharmaceuticals, Inc., an estimated $90.8M.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, down from 69% a quarter earlier, followed by Financials and Consumer Discretionary.

  • Deerfield Management's largest Q2 2019 buy was MALLINCKRODT PUBLIC LIMITED COMPANY: 4,178,219 shares worth $38.4M.
  • Deerfield Management added most to Viatris in Q2 2019, an estimated $94.3M increase.
  • Deerfield Management's biggest Q2 2019 reduction was Centene, cutting an estimated $19.7M.
  • Deerfield Management fully exited Portola Pharmaceuticals, Inc. in Q2 2019, selling an estimated $90.8M.
  • Deerfield Management's ten largest holdings make up 39% of its $2.78B portfolio in Q2 2019.
  • Deerfield Management opened 17 new positions and closed 12 in Q2 2019.
  • Deerfield Management's portfolio value rose 6.8% quarter-over-quarter to $2.78B.

Based on Deerfield Management's 13F filing for Q2 2019, filed 14 Aug 2019.